Cargando…

DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents

Antibody drug conjugates (ADC), comprised of highly potent small molecule payloads chemically conjugated to a full-length antibody, represent a growing class of therapeutic agents. The targeting of cytotoxic payloads via the specificity and selectivity of the antibody has led to substantial clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chooniedass, Shilpa, Dillon, Rachelle L., Premsukh, Arjune, Hudson, Peter J., Adams, Gregory P., MacDonald, Glen C., Cizeau, Jeannick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6273041/ https://www.ncbi.nlm.nih.gov/pubmed/27999336 http://dx.doi.org/10.3390/molecules21121741

Ejemplares similares

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients
por: Kowalski, Mark, et al.
Publicado: (2010)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck
por: MacDonald, Glen C, et al.
Publicado: (2009)

Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity
por: Mølgaard, K, et al.
Publicado: (2017)

Generation and Characterization of a Diabody Targeting the α(v)β(6) Integrin
por: Kogelberg, Heide, et al.
Publicado: (2013)

Inhibition activity of a disulfide-stabilized diabody against basic fibroblast growth factor in lung cancer
por: Cai, Yaxiong, et al.
Publicado: (2017)

Fermentation, Purification, and Tumor Inhibition of a Disulfide-Stabilized Diabody Against Fibroblast Growth Factor-2
por: Zhang, Simin, et al.
Publicado: (2021)

The E1B 19K/Bcl-2–binding Protein Nip3 is a Dimeric Mitochondrial Protein that Activates Apoptosis
por: Chen, Gao, et al.
Publicado: (1997)

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
por: Adams, G. P., et al.
Publicado: (1998)

Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface
por: Kim, Jin Hong, et al.
Publicado: (2016)

Distinguishing Between Monomeric scFv and Diabody in Solution Using Light and Small Angle X-ray Scattering
por: Lüdel, Frank, et al.
Publicado: (2019)

Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation
por: Kuwahara, Atsushi, et al.
Publicado: (2020)

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
por: Nguyen, Toan D., et al.
Publicado: (2023)

Construction of a disulfide‐stabilized diabody against fibroblast growth factor‐2 and the inhibition activity in targeting breast cancer
por: Cai, Yaxiong, et al.
Publicado: (2016)

Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity
por: Asano, Ryutaro, et al.
Publicado: (2018)

Those ADCs
Publicado: (1971)

First clinical study of a pegylated diabody (124)I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers
por: Scott, Andrew M., et al.
Publicado: (2020)

ADC : analog-to-digital converter reference manual.

The Chemistry Behind ADCs
por: Kostova, Vesela, et al.
Publicado: (2021)

Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2
por: Behdani, Mahdi, et al.
Publicado: (2012)

Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats
por: Asano, Ryutaro, et al.
Publicado: (2020)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
por: Yuan, Qingyun, et al.
Publicado: (2021)

Evaluating the Scope of Malignant Bone Tumor Using ADC Measurement on ADC Map
por: Chen, Haisong, et al.
Publicado: (2019)

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
por: Bühler, P., et al.
Publicado: (2007)

LAr LTDB ADC’s calibration
por: Estevam De Paula, Rodrigo
Publicado: (2021)

Preamplifier/Shapers & ADC for Calorimeters
por: Schwemling, Philippe
Publicado: (2018)

Current ADC Linker Chemistry
por: Jain, Nareshkumar, et al.
Publicado: (2015)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability
por: Lambregts, Doenja M. J., et al.
Publicado: (2011)

Diffusion-Weighted Imaging for the Discrimination of Benign and Malignant Breast Masses; Utility of ADC and Relative ADC
por: Yılmaz, Ebru, et al.
Publicado: (2018)

Differentiation of Benign and Malignant Breast Lesions Using ADC Values and ADC Ratio in Breast MRI
por: Tsvetkova, Silvia, et al.
Publicado: (2022)

The AdcACB/AdcAII system is essential for zinc homeostasis and an important contributor of Enterococcus faecalis virulence
por: Lam, Ling Ning, et al.
Publicado: (2022)

Design and preclinical evaluation of a (99m)Tc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)
por: Kampmeier, Florian, et al.
Publicado: (2014)

Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics
por: Asano, Ryutaro, et al.
Publicado: (2014)

Linearity investigation of ADC-TDC modules
por: Kulish, E, et al.
Publicado: (2011)

Systematic design for optimisation of pipelined ADCs
por: Goes, Joao
Publicado: (2001)

Endometrial Cancer Staging: Is There Value in ADC?
por: Moreira, Ana Sofia Linhares, et al.
Publicado: (2023)

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
por: Koster, Kira-Lee, et al.
Publicado: (2022)

Psychometric properties of the Alzheimer’s Disease Cooperative Study – Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial
por: Potashman, Michele, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gcfc384cl19h72mhs6i31v57pn